Karyopharm Therapeutics Inc. Quarterly Share-based Payment Arrangement, Expense in USD from Q3 2012 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Karyopharm Therapeutics Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q3 2012 to Q3 2024.
  • Karyopharm Therapeutics Inc. Share-based Payment Arrangement, Expense for the quarter ending September 30, 2024 was $4.18M, a 17.6% decline year-over-year.
  • Karyopharm Therapeutics Inc. Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2024 was $19.7M, a 13% decline year-over-year.
  • Karyopharm Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2023 was $21.7M, a 38.7% decline from 2022.
  • Karyopharm Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2022 was $35.4M, a 18.9% increase from 2021.
  • Karyopharm Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2021 was $29.8M, a 22% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $19.7M $4.18M -$896K -17.6% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-05
Q2 2024 $20.6M $5.41M -$650K -10.7% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-06
Q1 2024 $21.3M $4.97M -$419K -7.78% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-08
Q4 2023 $21.7M $5.18M -$991K -16.1% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-29
Q3 2023 $22.7M $5.08M -$1.72M -25.3% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-05
Q2 2023 $24.4M $6.06M -$9.03M -59.8% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-06
Q1 2023 $33.5M $5.39M -$1.95M -26.5% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
Q4 2022 $35.4M $6.17M -$696K -10.1% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-29
Q3 2022 $36.1M $6.8M -$623K -8.4% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-02
Q2 2022 $36.7M $15.1M +$6.96M +85.5% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-02
Q1 2022 $29.8M $7.34M -$23K -0.31% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-04
Q4 2021 $29.8M $6.87M +$555K +8.79% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-29
Q3 2021 $29.2M $7.42M +$907K +13.9% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 $28.3M $8.14M +$1.71M +26.6% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 $26.6M $7.36M +$2.21M +42.8% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-05
Q4 2020 $24.4M $6.31M +$2.77M +77.9% Oct 1, 2020 Dec 31, 2020 10-K 2023-02-17
Q3 2020 $21.6M $6.51M +$2.79M +75.1% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-03
Q2 2020 $18.8M $6.43M +$2.31M +56.2% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-05
Q1 2020 $16.5M $5.15M +$1.25M +31.9% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-04
Q4 2019 $15.3M $3.55M Oct 1, 2019 Dec 31, 2019 10-K 2022-03-01
Q3 2019 $3.72M Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-02
Q2 2019 $4.12M Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-04
Q1 2019 $3.91M Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-05
Q3 2013 $1.32M +$1.17M +748% Jul 1, 2013 Sep 30, 2013 10-Q/A 2013-12-23
Q3 2012 $156K Jul 1, 2012 Sep 30, 2012 10-Q/A 2013-12-23
* An asterisk sign (*) next to the value indicates that the value is likely invalid.